These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34253637)

  • 1. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
    Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
    J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
    Park JA; Cheung NV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.
    Sandker GGW; Middelburg J; Wilbrink E; Molkenboer-Kuenen J; Aarntzen E; van Hall T; Heskamp S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.
    Wang L; Jiang H; Yin X; Liang T; Li G; Ding C; Yang M; Zhang L; Liu J; Xu Y
    Front Immunol; 2024; 15():1415834. PubMed ID: 38933272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
    Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
    Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
    Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
    MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
    Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
    Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency.
    Wang L; Hoseini SS; Xu H; Ponomarev V; Cheung NK
    Cancer Immunol Res; 2019 Dec; 7(12):2013-2024. PubMed ID: 31615814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
    Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
    Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.